Get the Stockscreener App
5.93
1.82%
-0.11
Cumberland Pharmaceuticals Inc stock is traded at $5.93, with a volume of 48,413.
It is down -1.82% in the last 24 hours and up +8.21% over the past month.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.
See More
Previous Close:
$6.04
Open:
$6.07
24h Volume:
48,413
Relative Volume:
0.05
Market Cap:
$88.85M
Revenue:
$41.94M
Net Income/Loss:
$-7.40M
P/E Ratio:
-12.02
EPS:
-0.4935
Net Cash Flow:
$1.29M
1W Performance:
-6.91%
1M Performance:
+8.21%
6M Performance:
+19.80%
1Y Performance:
+77.54%
1-Day Range:
$5.76
$6.1451
1-Week Range:
$5.76
$6.75
52-Week Range:
$1.85
$7.355
Cumberland Pharmaceuticals Inc Stock (CPIX) Company Profile
Name
Cumberland Pharmaceuticals Inc
Sector
Phone
615-255-0068
Address
1600 WEST END AVENUE, NASHVILLE,, TN
Compare CPIX vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPIX
Cumberland Pharmaceuticals Inc
|
5.93 | 88.85M | 41.94M | -7.40M | 1.29M | -0.4935 |
TAK
Takeda Pharmaceutical Co Adr
|
16.56 | 52.88B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.76 | 42.98B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.95 | 38.37B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.56 | 31.68B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.06 | 23.22B | 3.17B | 1.29B | 1.01B | 27.09 |
Cumberland Pharmaceuticals Inc Stock (CPIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-12-12 | Reiterated | UBS | Neutral |
| Feb-01-11 | Reiterated | UBS | Neutral |
| Dec-16-10 | Downgrade | UBS | Buy → Neutral |
| Aug-17-10 | Downgrade | Jefferies | Buy → Hold |
| Aug-17-10 | Reiterated | Morgan Joseph | Buy |
| Aug-17-10 | Reiterated | UBS | Buy |
| May-14-10 | Reiterated | Morgan Joseph | Buy |
View All
Cumberland Pharmaceuticals Inc Stock (CPIX) Latest News
Cumberland outlines new product expansion and sees $8.3M Q3 revenues while advancing clinical pipeline - MSN
Cumberland Pharmaceuticals Sells Branded Drug Portfolio to Apotex for $100M, Refocuses on Rare Disease Pipeline 1 - Minichart
CPIXCumberland Pharmaceuticals Inc Latest SEC Filings - Finviz
Cumberland Refocuses on Rare Disease Pipeline After Asset Sale - TipRanks
Cumberland (CPIX) nets $100M from Apotex deal, shifts to rare disease pipeline - Stock Titan
Cumberland Pharmaceuticals closes $100 million sale of drug portfolio - The Business Journals
Cumberland sells branded drug portfolio to Apotex for $100m By Investing.com - Investing.com South Africa
Cumberland sells branded drug portfolio to Apotex for $100m - Investing.com
Apotex Completes Previously Announced Strategic Transaction with Cumberland Pharmaceuticals - The Globe and Mail
Cumberland sells branded U.S. drugs to Apotex for $100M - Stock Titan
Cumberland Pharma advances Duchenne program with new safety, efficacy data - MSN
Cumberland Pharma Advances Duchenne Program With New Safety, Efficacy Data - Sahm
Cumberland shares updated trial results for DMD heart therapy - Investing.com UK
Why Is Cumberland Pharma Stock Gaining Friday?Cumberland Pharma (NASDAQ:CPIX) - Benzinga
Cumberland says updated DMD heart data strengthen ifetroban case - Stock Titan
Cumberland Pharmaceuticals Inc (CPIX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Shareholders back Cumberland (NASDAQ: CPIX) sale of most assets - Stock Titan
Cumberland Pharmaceuticals Inc (CPIX) Institutional Confidence - TradingKey
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement - Sahm
RedHill closes $6M financing, with up to $13.4M more possible - Stock Titan
Cumberland Pharmaceuticals Inc (CPIX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cumberland Pharmaceuticals Inc (CPIX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cumberland Pharmaceuticals Inc (CPIX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cumberland Pharmaceuticals Inc (CPIX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
RedHill Biopharma raises $6M now, with $13.4M more tied to warrants - Stock Titan
Cumberland Pharmaceuticals Inc - TradingKey
Cumberland Pharmaceuticals Inc (CPIX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cumberland Pharmaceuticals Inc (CPIX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CPIX News | CUMBERLAND PHARMACEUTICALS (NASDAQ:CPIX) - ChartMill
CPIX Q1 2026 Earnings: Narrowing Losses Amidst Operational UncertaintyEPS Surprise History - newsline.com
Cumberland Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Brown Martin S JR - Moomoo
Cumberland Pharmaceuticals (CPIX) Slips 0.79% as Stock Hovers Near Key Support LevelFundamentals - dars.gov.et
RedHill moves to enforce $10.9M New York judgment on Kukbo in Korea - Stock Titan
Cumberland Pharmaceuticals (CPIX) Extends Decline Amid Low Volume PressurePrice Target - newsline.com
Cumberland shares soar on $100M deal announcement - Nashville Post
Cumberland reports positive phase 2a cancer trial results - Investing.com UK
Cumberland reports positive phase 2a cancer trial results By Investing.com - Investing.com Canada
Cumberland Pharmaceuticals And Vanderbilt Announce Phase 2A Trial Data For ifetroban In High-Risk Solid Tumors - TradingView
Early trial hints at drug to cut risk of cancer returning after treatment - Stock Titan
Pilot Study Demonstrates Safety of Ifetroban for Patients With High-Risk Solid Tumors, Suggests Potential to Block Cancer Metastasis | Newswise - Newswise
Cumberland Pharmaceuticals (CPIX) Rises 2.84%: Support Holds as Stock Approaches ResistanceTrend Following Picks - dars.gov.et
Cumberland Pharmaceuticals (CPIX) Gains Momentum: Up 2.84% on Normal Trading ActivityIV Percentile - The Legal Advocate
Cumberland Pharma Stock Rises After China Antibiotic Launch — Why Investors Are Watching - Bez Kabli
Cumberland Pharmaceuticals Hits New 52-Week High of $6.51 - MarketsMojo
CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA - Citizen Tribune
Number of shareholders of Cumberland Pharmaceuticals Inc. – NASDAQ:CPIX - TradingView
The Zacks Analyst Blog Highlights Alphabet, Apple, Micron Technology, Cumberland Pharmaceuticals and AmeriServ Financial - Yahoo Finance
New MRSA-fighting antibiotic Vibativ now available to patients in China - Stock Titan
CPIX Q1 2026 Earnings: Net Loss Reported, Shares Edge HigherGuidance Revision Trend - The Legal Advocate
CPIX Q1 2026 Earnings: Narrowing Losses and Strategic Progress Amidst Revenue ChallengesDividend Increase Stocks - The Legal Advocate
Cumberland Pharmaceuticals(CPIX) Stock Options Chain | Quotes & News - Moomoo
Cumberland Pharmaceuticals Inc Stock (CPIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.42%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):